WEBULL
News
NSPRZ
0.0090
0.00%
0.00
InspireMD Director Paul Stuka Reports Acquisition of Common Shares
Reuters · 12/11 21:06
INSPIREMD ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/21 14:00
InspireMD Q3 revenue beats estimates on commercial launch of CGuard Prime
Reuters · 11/04 12:13
INSPIREMD NAMES PETER A. SOUKAS, M.D., AS CHIEF MEDICAL OFFICER
Reuters · 11/03 12:30
INSPIREMD ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 10/08 12:00
INSPIREMD ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 09/25 20:05
InspireMD Inc. Files Initial Statement of Beneficial Ownership for Director Danny L. Dearen
Reuters · 09/24 20:00
InspireMD Inc. Appoints Dan Dearen to Board of Directors Amid U.S. Launch of CGuard Prime
Reuters · 09/17 12:01
InspireMD Inc. Updates SEC Filing to Announce Board Committee Appointments for Director Raymond W. Cohen
Reuters · 09/08 20:06
InspireMD Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters · 08/05 13:31
Stent maker InspireMD's Q2 revenue beats estimates
Reuters · 08/05 12:09
InspireMD Inc. Files Initial Statement of Beneficial Ownership for Director Raymond W. Cohen
Reuters · 08/01 21:38
Marvin Slosman, CEO and President, Reports Acquisition of Common Shares in InspireMD Inc
Reuters · 08/01 21:00
Gary S. Roubin, Director, Reports Acquisition of Common Shares of InspireMD Inc
Reuters · 08/01 21:00
InspireMD Inc. Appoints Raymond W. Cohen to Board of Directors, Enhancing Leadership with MedTech Veteran
Reuters · 07/31 12:44
InspireMD Secures $58 Million in Funding Following FDA Approval of CGuard Prime Carotid Stent
Reuters · 07/31 12:36
INSPIREMD ANNOUNCES U.S. COMMERCIAL LAUNCH OF CGUARD® PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE
Reuters · 07/09 11:01
INSPIREMD ANNOUNCES FDA APPROVAL FOR CGUARD® PRIME CAROTID STENT SYSTEM FOR THE PREVENTION OF STROKE
Reuters · 06/24 20:05
INSPIREMD INC - FDA APPROVAL TRIGGERS SECOND WARRANT TRANCHE IN $113.6 MLN FINANCING
Reuters · 06/24 20:05
INSPIREMD ANNOUNCES APPOINTMENT OF MICHAEL LAWLESS AS CHIEF FINANCIAL OFFICER
Reuters · 06/03 20:05
More
Webull provides a variety of real-time NSPRZ stock news. You can receive the latest news about Inspiremd through multiple platforms. This information may help you make smarter investment decisions.
About NSPRZ
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.